Burning Rock Biotech Limited
Price Action
Technical Summary
WEAKENINGBurning Rock Biotech Limited is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 6), showing significant lag compared to the market leaders. Earnings growth of 81% provides fundamental context to the price action. Investors should exercise caution due to high volatility (137% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $8.40 | -3.84% | BELOW |
| 50 SMA | $13.55 | -40.35% | BELOW |
| 100 SMA | $18.09 | -55.32% | BELOW |
| 150 SMA | $20.06 | -59.73% | BELOW |
| 200 SMA | $17.62 | -54.15% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BNR in an uptrend right now?
BNR has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is BNR overbought or oversold?
BNR's RSI (14) is 39. The stock is in neutral territory, neither overbought nor oversold.
Is BNR outperforming the market?
BNR has a Relative Strength (RS) Rating of 6 out of 99. BNR is currently lagging the broader market.
Where is BNR in its 52-week range?
BNR is trading at $8.08, which is 19% of its 52-week high ($41.72) and 13% above its 52-week low ($3.11).
How volatile is BNR?
BNR has a Beta of 2.05 and 52-week volatility of 137%. It's more volatile than the S&P 500 - expect bigger swings.